Patent provides the company broad coverage on the use of menaquinones in food and supplements for cardiovascular health.
NattoPharma ASA has announced that its patent application—#09/850,804 (“ex‐Unilever”) re. “Vitamin K2 Containing Food product”—has now been published in the U.S. by the United States Patent and Trade Office, with the Patent No. 8,354,129.
According to Dr. Hogne Vik, CEO of NattoPharma, this newly published patent strengthens NattoPharma's IPR and commercial platform in the U.S. The patent provides NattoPharma a broad coverage on the use of menaquinones (vitamin K2) in the preparation of food and dietary supplements for maintaining, optimizing, strengthening or promoting cardiovascular health.
"The approval of the patent represents a milestone for NattoPharma and our partners in the US market," Vik says. This will strengthen NattoPharma's global IPR‐platform and improve our competitive position in the United States within the food supplement market as well as the functional food market."
Vik adds that NattoPharma has made significant intellectual and monetary investments in technologies and are committed to actively monitoring market developments to protect their intellectual property rights throughout their lifespan.